Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1038/s41576-022-00450-3 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Current Treatment Regimens and Promising Molecular Therapies for Chronic Hepatobiliary Diseases.
Biomolecules
January 2025
Institute for Biostructure and Bioimaging, National Research Council, Molecular Biotechnology Centre "Guido Tarone", 10126 Turin, Italy.
Chronic hepatobiliary damage progressively leads to fibrosis, which may evolve into cirrhosis and/or hepatocellular carcinoma. The fight against the increasing incidence of liver-related morbidity and mortality is challenged by a lack of clinically validated early-stage biomarkers and the limited availability of effective anti-fibrotic therapies. Current research is focused on uncovering the pathogenetic mechanisms that drive liver fibrosis.
View Article and Find Full Text PDFAntioxidative and Anticancer Potential of Luteolin: A Comprehensive Approach Against Wide Range of Human Malignancies.
Food Sci Nutr
January 2025
Faculty of Chemical and Food Engineering, Bahir Dar Institute of Technology Bahir Dar University Bahir Dar Ethiopia.
Luteolin is widely distributed phytochemical, a flavonoid, in kingdom plantae. Luteolin with potential antioxidant activity prevent ROS-induced damages and reduce oxidative stress which is mainly responsible in pathogenesis of many diseases. Several chemo preventive activities and therapeutic benefits are associated with luteolin.
View Article and Find Full Text PDFHistone Deacetylase (HDAC) Inhibitors as a Novel Therapeutic Option Against Fibrotic and Inflammatory Diseases.
Biomolecules
December 2024
Department of Chemistry, National and Kapodistrian University of Athens, 15771 Athens, Greece.
Histone deacetylases (HDACs) are enzymes that play an essential role in the onset and progression of cancer. As a consequence, a variety of HDAC inhibitors (HDACis) have been developed as potent anticancer agents, several of which have been approved by the FDA for cancer treatment. However, recent accumulated research results have suggested that HDACs are also involved in several other pathophysiological conditions, such as fibrotic, inflammatory, neurodegenerative, and autoimmune diseases.
View Article and Find Full Text PDFRadiation therapy-induced normal tissue damage: involvement of EMT pathways and role of FLASH-RT in reducing toxicities.
Radiat Environ Biophys
January 2025
Department of Pharmacology, Chettinad Hospital and Research Institute, Chettinad Academy of Research and Education, Kelambakkam, India.
Article Synopsis
- Radiation therapy (RT) is crucial for cancer treatment but often damages surrounding normal tissues, leading to complications like fibrosis and decreased organ function.
- Conventional RT promotes epithelial-mesenchymal transition (EMT), which is linked to tissue damage and cancer progression.
- FLASH radiation therapy (FLASH-RT) offers a promising alternative by delivering high doses rapidly, potentially reducing normal tissue damage while preserving regenerative capacity and mitigating fibrosis through improved regulation of EMT pathways.
A novel sustained-release agent based on disulfide-induced recombinant collagen hydrogels for the prevention and treatment of infections.
Microbiol Spectr
December 2024
Ministry of Education Key Laboratory of Industrial Biotechnology, School of Biotechnology, Jiangnan University, Wuxi, China.
Schistosomiasis is commonly managed using the praziquantel, but it is only effective against adult worms and duration of action is short. Liver fibrosis will worsen if eggs are still present after stopping treatment. Therefore, this study aimed to develop a sustained drug release system for effectively preventing and treating schistosomiasis.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!